# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and lowers the price ta...
HC Wainwright & Co. analyst Andrew Fein maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price t...
Citigroup analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30...
Stifel analyst Paul Matteis maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Hold and lowers the price target from $26 ...
Cantor Fitzgerald analyst Charles Duncan reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and maintains $37...
Mizuho analyst Uy Ear maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and lowers the price target from $25 to ...
Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $30 price target.
Baird analyst Joel Beatty maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from ...
Acadia is reiterating all of its 2024 guidance provided on February 27, 2024.DAYBUE net product sales guidance in the range of ...